<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100203</url>
  </required_header>
  <id_info>
    <org_study_id>ALBLOCK-2</org_study_id>
    <nct_id>NCT01100203</nct_id>
  </id_info>
  <brief_title>Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function</brief_title>
  <acronym>ALBLOCK-2</acronym>
  <official_title>Aldosterone Blockade in Chronic Kidney Disease. Influence on Arterial Stiffness and Kidney Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lene Boesby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Chronic Kidney Disease (CKD) have a poor prognosis primarily due to&#xD;
      cardiovascular disease. The cardiovascular risk can be assessed by measurements of arterial&#xD;
      stiffness. A decrease in stiffness has been shown to decrease the risk of cardiovascular&#xD;
      disease as well as death. Most of the CKD population also have hypertension and the control&#xD;
      of blood pressure is one of the corner stones in inhibition of disease progression. Using&#xD;
      drugs that specifically block the renin-angiotensin-system for blood pressure control has&#xD;
      been shown to have a beneficial impact on inhibition of progression beyond that of the&#xD;
      achieved blood pressure control. It has been reported that inhibition of the hormone&#xD;
      aldosterone has a positive effect on survival in patients with heart failure, hypertension&#xD;
      and diabetic as well as on-diabetic nephropathy.&#xD;
&#xD;
      This study undertakes the investigation of the influence on arterial stiffness of adding an&#xD;
      aldosterone receptor inhibitor to the medication CKD patients are already taking. Besides the&#xD;
      primary end point which is Pulse wave velocity (PWV), arterial stiffness is also quantified&#xD;
      thorough ambulatory blood pressure measurements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It was not possible within the time frame to recruit the planned no. of patients.&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pulse wave velocity measured using the SphygmoCor device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse Wave velocity</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulatory arterial stiffness index</measure>
    <time_frame>24 weeks</time_frame>
    <description>24 hour ambulatory blood pressure measurements, give rise to the index, which is a secondary measure of arterial compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave analysis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Parameters are Augmentation Index, subendocardial viability ratio, pulse, time to reflection, ejection duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>baseline</time_frame>
    <description>Will be calculated from 24 hour urine collections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave analysis</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory arterial stiffness index</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory arterial stiffness index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave analysis</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>baseline</time_frame>
    <description>Estimated glomerular filtration rate (eGFR) will be calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium</measure>
    <time_frame>week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>baseline</time_frame>
    <description>BP will be measured at all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years age ≤ 80 years age&#xD;
&#xD;
          -  voluntarily signed informed consent&#xD;
&#xD;
          -  15 ml/min/1,73 m2 ≤ estimated Glomerular Filtration Rate &lt; 60 ml/min/1,73 m2&#xD;
&#xD;
          -  BP ≥ 130/80 mmHg or undergoing anti-hypertensive treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  p-potassium is &gt; 5.0 mM&#xD;
&#xD;
          -  allergy to contents&#xD;
&#xD;
          -  treated with spironolactone&#xD;
&#xD;
          -  treated with potent inhibitors of CYP3A4 (see SPC for details)&#xD;
&#xD;
          -  treated with lithium, ciclosporin, tacrolimus, prednisolone, or other&#xD;
             immunosuppressing drug&#xD;
&#xD;
          -  inborn errors of metabolism (see SPC for details)&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  fertile woman, not using safe contraception devices&#xD;
&#xD;
          -  dementia or other psychiatric disorder, making understanding of the study conditions&#xD;
             impossible&#xD;
&#xD;
          -  other severe, chronic illness besides CKD, including liver insufficiency, according to&#xD;
             investigators' judgement&#xD;
&#xD;
          -  vascular surgery including stenting or graft implantation on a. brachialis, aorta or&#xD;
             the carotid arteries&#xD;
&#xD;
          -  systolic BP &gt; 200 mmHg&#xD;
&#xD;
          -  immeasurable pulse amplitude&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lene Boesby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Nephrology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <last_update_submitted>February 7, 2012</last_update_submitted>
  <last_update_submitted_qc>February 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Lene Boesby</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>aldosterone receptor inhibition</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>ambulatory arterial stiffness index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

